145 related articles for article (PubMed ID: 10609816)
1. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study.
Vanharanta M; Voutilainen S; Lakka TA; van der Lee M; Adlercreutz H; Salonen JT
Lancet; 1999 Dec 18-25; 354(9196):2112-5. PubMed ID: 10609816
[TBL] [Abstract][Full Text] [Related]
2. Serum enterolactone concentration and the risk of coronary heart disease in a case-cohort study of Finnish male smokers.
Kilkkinen A; Erlund I; Virtanen MJ; Alfthan G; Ariniemi K; Virtamo J
Am J Epidemiol; 2006 Apr; 163(8):687-93. PubMed ID: 16510545
[TBL] [Abstract][Full Text] [Related]
3. Serum enterolactone concentration is not associated with prostate cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Virtanen MJ; Adlercreutz H; Albanes D; Pietinen P
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1209-12. PubMed ID: 14652283
[TBL] [Abstract][Full Text] [Related]
4. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.
Kilkkinen A; Virtamo J; Vartiainen E; Sankila R; Virtanen MJ; Adlercreutz H; Pietinen P
Int J Cancer; 2004 Jan; 108(2):277-80. PubMed ID: 14639615
[TBL] [Abstract][Full Text] [Related]
5. Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study.
Vanharanta M; Voutilainen S; Rissanen TH; Adlercreutz H; Salonen JT
Arch Intern Med; 2003 May; 163(9):1099-104. PubMed ID: 12742810
[TBL] [Abstract][Full Text] [Related]
6. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
Pietinen P; Stumpf K; Männistö S; Kataja V; Uusitupa M; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2001 Apr; 10(4):339-44. PubMed ID: 11319174
[TBL] [Abstract][Full Text] [Related]
7. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.
Stattin P; Adlercreutz H; Tenkanen L; Jellum E; Lumme S; Hallmans G; Harvei S; Teppo L; Stumpf K; Luostarinen T; Lehtinen M; Dillner J; Hakama M
Int J Cancer; 2002 May; 99(1):124-9. PubMed ID: 11948503
[TBL] [Abstract][Full Text] [Related]
8. Determinants of serum enterolactone concentration.
Kilkkinen A; Stumpf K; Pietinen P; Valsta LM; Tapanainen H; Adlercreutz H
Am J Clin Nutr; 2001 Jun; 73(6):1094-100. PubMed ID: 11382665
[TBL] [Abstract][Full Text] [Related]
9. Plasma enterolactone and breast cancer incidence by estrogen receptor status.
Olsen A; Knudsen KE; Thomsen BL; Loft S; Stripp C; Overvad K; Møller S; Tjønneland A
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2084-9. PubMed ID: 15598765
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of plasma enterolactone and prostate cancer risk (Sweden).
Stattin P; Bylund A; Biessy C; Kaaks R; Hallmans G; Adlercreutz H
Cancer Causes Control; 2004 Dec; 15(10):1095-102. PubMed ID: 15801493
[TBL] [Abstract][Full Text] [Related]
11. Validation of FFQ-based assessment of dietary lignans compared with serum enterolactone in Swedish women.
Lin Y; Wolk A; Håkansson N; Peñalvo JL; Lagergren J; Adlercreutz H; Lu Y
Br J Nutr; 2013 May; 109(10):1873-80. PubMed ID: 23006454
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum enterolactone, genistein, and daidzein in a dietary intervention study in Finland.
Stumpf K; Pietinen P; Puska P; Adlercreutz H
Cancer Epidemiol Biomarkers Prev; 2000 Dec; 9(12):1369-72. PubMed ID: 11142423
[TBL] [Abstract][Full Text] [Related]
13. Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.
Sonestedt E; Borgquist S; Ericson U; Gullberg B; Olsson H; Adlercreutz H; Landberg G; Wirfält E
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3241-51. PubMed ID: 18990767
[TBL] [Abstract][Full Text] [Related]
14. Association between low serum enterolactone and increased plasma F2-isoprostanes, a measure of lipid peroxidation.
Vanharanta M; Voutilainen S; Nurmi T; Kaikkonen J; Roberts LJ; Morrow JD; Adlercreutz H; Salonen JT
Atherosclerosis; 2002 Feb; 160(2):465-9. PubMed ID: 11849672
[TBL] [Abstract][Full Text] [Related]
15. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.
Guglielmini P; Rubagotti A; Boccardo F
Breast Cancer Res Treat; 2012 Apr; 132(2):661-8. PubMed ID: 22094938
[TBL] [Abstract][Full Text] [Related]
16. Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden).
Hedelin M; Klint A; Chang ET; Bellocco R; Johansson JE; Andersson SO; Heinonen SM; Adlercreutz H; Adami HO; Grönberg H; Bälter KA
Cancer Causes Control; 2006 Mar; 17(2):169-80. PubMed ID: 16425095
[TBL] [Abstract][Full Text] [Related]
17. Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men.
Wallström P; Drake I; Sonestedt E; Gullberg B; Bjartell A; Olsson H; Adlercreutz H; Tikkanen MJ; Wirfält E
Eur J Nutr; 2018 Oct; 57(7):2595-2606. PubMed ID: 28884432
[TBL] [Abstract][Full Text] [Related]
18. Use of oral antimicrobials decreases serum enterolactone concentration.
Kilkkinen A; Pietinen P; Klaukka T; Virtamo J; Korhonen P; Adlercreutz H
Am J Epidemiol; 2002 Mar; 155(5):472-7. PubMed ID: 11867359
[TBL] [Abstract][Full Text] [Related]
19. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
Piller R; Chang-Claude J; Linseisen J
Eur J Cancer Prev; 2006 Jun; 15(3):225-32. PubMed ID: 16679865
[TBL] [Abstract][Full Text] [Related]
20. Time-resolved fluoroimmunoassay for plasma enterolactone.
Adlercreutz H; Wang GJ; Lapcík O; Hampl R; Wähälä K; Mäkelä T; Lusa K; Talme M; Mikola H
Anal Biochem; 1998 Dec; 265(2):208-15. PubMed ID: 9882394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]